Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CO-LAV vs ANDROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
mild to moderate pain,fever,inflammation
Primary hypogonadism (congenital or acquired),Hypogonadotropic hypogonadism,Off-label: delayed puberty in males, certain breast cancers
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
Unknown
The terminal elimination half-life of testosterone from Andro Gel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Codeine is metabolized via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine, with further glucuronidation. Aspirin is rapidly hydrolyzed to salicylate by esterases in the gastrointestinal tract and liver; salicylate is primarily metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Hepatic via CYP3A4, CYP2C9, and 17β-hydroxysteroid dehydrogenase; metabolites include estradiol and dihydrotestosterone.
CO-LAV is not a recognized drug. Please check the drug name.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Unknown
Approximately 98% of circulating testosterone is protein-bound: 40-50% bound to sex hormone-binding globulin (SHBG) and 50-60% loosely bound to albumin.
Unknown
The apparent volume of distribution of testosterone is about 1.0 L/kg, reflecting extensive distribution into tissues, particularly muscle, skin, and male reproductive organs.
Unknown
Bioavailability of testosterone from Andro Gel is approximately 10-14% of the applied dose, due to limited skin permeation and first-pass metabolism (though minimal with transdermal route). For comparison, oral testosterone bioavailability is <1%, while intramuscular testosterone enanthate has 100% bioavailability.
GFR 15-30 m L/min: administer 50% of standard dose every 12 hours; GFR <15 m L/min: contraindicated (except during hemodialysis, where 50% dose post-dialysis may be used).
No specific dose adjustment is provided for renal impairment. Use with caution in patients with severe renal impairment due to potential for fluid retention.
Child-Pugh Class A/B: no adjustment necessary; Child-Pugh Class C: contraindicated due to risk of severe hepatotoxicity.
Contraindicated in patients with Child-Pugh class C (severe hepatic impairment). Use with caution and monitor liver function in mild to moderate hepatic impairment; no specific dose reduction guidelines exist.
Children >2 months: 8 mg/kg/day (based on trimethoprim) in two divided doses for UTI; for PCP prophylaxis: 150 mg/m²/day in two divided doses on 3 consecutive days per week.
Not indicated in pediatric patients under 18 years of age; safety and efficacy have not been established.
Increased risk of severe adverse reactions (e.g., hyperkalemia, renal impairment); monitor renal function and potassium levels; initiate at lower doses (e.g., half the standard dose) and titrate cautiously.
Elderly patients may be more sensitive to androgens, and require careful monitoring for prostate enlargement, prostate cancer, and fluid retention. Start at the lowest dose (25 mg daily) and titrate based on serum testosterone levels and clinical response.
Codeine is contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death associated with ultra-rapid metabolism of codeine to morphine. Aspirin is associated with Reye's syndrome in children and adolescents with viral illnesses.
None.
Respiratory depression, risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression in children with CYP2D6 ultra-rapid metabolizers; Reye's syndrome in children and adolescents with viral illnesses; increased risk of bleeding; gastrointestinal perforation and bleeding; renal impairment; hypersensitivity reactions including anaphylaxis and aspirin-sensitive asthma; drug interactions with CYP2D6 and CYP3A4 inhibitors/inducers; use in pregnancy and lactation.
Risk of secondary exposure to testosterone (children) – avoid skin contact,Polycythemia (monitor hematocrit),Prostate enlargement/cancer risk,Cardiovascular risk (especially in elderly),Spermatogenesis suppression,Hepatic effects (monitor liver function),Edema (in patients with preexisting conditions)
Hypersensitivity to codeine, aspirin, or NSAIDs; children younger than 12 years; children younger than 18 years following tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; bleeding disorders; concomitant use with MAOIs or within 14 days; third trimester of pregnancy; nursing mothers (due to aspirin); viral illness with fever in children and adolescents (risk of Reye's syndrome); concomitant use with anticoagulants (e.g., warfarin) due to bleeding risk.
Known hypersensitivity to testosterone or gel components,Prostate cancer,Breast cancer (males),Women who are pregnant or may become pregnant (risk to fetus)
Grapefruit juice may increase colchicine levels due to CYP3A4 inhibition; avoid concurrent consumption. High-fat meals may reduce colchicine absorption? No data for colchicine specifically; take with or without food. Alcohol may worsen gout symptoms and increase risk of pancreatitis; avoid. Lactulose effect is not dependent on food; can be taken with or without meals.
No specific food interactions. Grapefruit juice may increase testosterone levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol intake as it may affect testosterone levels and liver function.
First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental transfer is minimal.
Andro Gel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus abnormalities) when exposed during the first trimester. Second and third trimester exposure may cause pseudohermaphroditism in females. Risk is highest during the first 12 weeks of gestation.
Considered compatible with breastfeeding. M/P ratio unknown; limited excretion into breast milk expected due to high protein binding and low oral bioavailability.
Testosterone is excreted into breast milk with an estimated M/P ratio of 0.1-0.3. It may cause virilization in nursing infants. Breastfeeding is not recommended during Andro Gel therapy.
No dose adjustment required for pregnancy. Pharmacokinetics are not significantly altered in pregnancy; standard dosing recommended.
Andro Gel is contraindicated in pregnancy; no dose adjustments are applicable. If exposure occurs, discontinue immediately and monitor for fetal effects.
CO-LAV (colchicine/lactulose) is a fixed-dose combination used for gout flare prophylaxis but poses risks in renal impairment; colchicine dose must be reduced in CKD stage 4-5 due to narrow therapeutic index. Lactulose may cause bloating and flatulence; monitor for diarrhea-related electrolyte disturbances. Avoid concurrent use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) and P-glycoprotein inhibitors (e.g., cyclosporine) to prevent colchicine toxicity. In liver impairment, colchicine accumulation can occur; use with caution. Geriatric patients are more susceptible to colchicine neurotoxicity and myopathy.
Apply to clean, dry, intact skin on shoulders, upper arms, or abdomen. Avoid application to genitals or chest due to higher absorption and risk of transfer. Wash hands after application. Allow gel to dry before dressing. Monitor serum testosterone, hematocrit, PSA, and lipid profile. Contraindicated in men with breast or prostate cancer. May cause erythrocytosis, sleep apnea, or worsening of BPH. Risk of testosterone transfer to women or children; cover application site or wash skin before contact.
Take this medication exactly as prescribed; do not exceed the recommended dose of colchicine.,If you have kidney or liver disease, inform your doctor; dose adjustments may be needed.,Report any signs of colchicine toxicity: muscle pain, weakness, numbness, tingling, or unusual bruising/bleeding.,Lactulose may cause gas, bloating, or stomach cramps; these usually improve over time.,Stay well hydrated to prevent diarrhea-related dehydration.,Do not take any other medications, including over-the-counter, without consulting your doctor.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks with your healthcare provider.,Store at room temperature away from moisture and heat.
Apply Andro Gel once daily at the same time each morning to clean, dry, intact skin on shoulders, upper arms, or abdomen.,Do not apply to genitals or chest.,Wash hands thoroughly with soap and water after application.,Allow gel to dry completely before dressing or coming into contact with others.,Avoid swimming, showering, or bathing for at least 5 hours after application.,If skin contact with another person is likely, cover the application site with clothing or wash the area before contact.,Keep Andro Gel away from children and women of childbearing potential.,Report any signs of deep vein thrombosis (leg swelling, pain, warmth), heart attack (chest pain, shortness of breath), or stroke (sudden weakness, confusion, vision changes).,Regular blood tests are required to monitor testosterone levels, red blood cell count, prostate health, and cholesterol.,Andro Gel may interact with blood thinners (e.g., warfarin) and corticosteroids; inform all healthcare providers.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CO-LAV vs ANDROGEL, answered by our medical review team.
CO-LAV is a Laxative/Bowel Evacuant that works by CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.. ANDROGEL is a Androgen that works by Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CO-LAV and ANDROGEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CO-LAV is: Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.. The standard adult dose of ANDROGEL is: 50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CO-LAV and ANDROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CO-LAV is classified as Category C. First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental t. ANDROGEL is classified as Category C. AndroGel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.